Apremilast Shows Low Persistence Among Patients with Psoriatic Arthritis

Results from a large observational retrospective cohort of ≥500 patients with PsA show relatively low drug persistence of apremilast, an oral PDE4 inhibitor.

Related Keywords

Israel ,Samir Haddad ,Carmel Medical Centre ,Carmel Medical ,